Why Value-based Contracts Are Still the Exception, per Chester "Bernie" Good at UPMC

,

Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.

Chester Good of UPMC Health Plan gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta.

He claimed that value-based contracts "still are the exception and not the rule."

The number of value-vased contracts any payer or health organization has is small rather than the number of durgs they provide. They aren't the answer to controlling drug costs but it's part of the answer.

It remains a niche or exception because they are a lot of work and require much time and thought. This is a big reason you don't see many contracts in the industry.